Overview

Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease

Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To explore the safety and efficiency of adenovirus-hepatocyte growth factor(Ad-HGF) treatment in ischemic heart disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborator:
Academy Military Medical Science, China
Treatments:
Mitogens